§01 Browse › LGD-3303

LGD-3303

LGD-3303
Moderate Suppression
Anabolic / Androgenic
90 8
11.2:1 vs testosterone baseline
Aromatizes No
Hepatotoxic No
Oral Yes
Suppression moderate
PCT Required

LGD-3303 is a second-generation analogue of LGD-4033 engineered for higher anabolic potency and a shorter 6-hour half-life. Animal studies show superior bone and muscle accrual versus its predecessor.

Protocol Why Use It Comparison Safety
Warning
Very limited human data · Requires multiple daily doses due to short half-life
Why people use it

LGD-3303 is typically discussed as a more strength-oriented or more acutely felt SARM than LGD-4033. That makes it attractive to users who want a sharper performance signal, but it also means less mainstream user experience exists to lean on.

Protocol & usage

Administration: Oral compound. Most users take it with a fixed daily schedule rather than chasing short-term effect swings.

Cycle context: Treat this like a suppressive research drug, not a harmless shortcut. Labs before and after matter even when the compound is marketed as mild.

Stop or reduce if: blood pressure climbs, sleep degrades, libido crashes, or labs move sharply in the wrong direction.

Notes

Bodybuilding Application

  • Rapid Lean Mass: Dry gains with minimal water retention; useful for in mini-cuts or lean bulk phases.
  • Frequent Dosing Flexibility: Short half-life allows precise timing; many dose pre-workout for maximal training aggression.
  • Stacks Well: Synergistic with peptides like IGF-1 or mild DHTs due to non-aromatizing nature.

Dosing Protocol

Because of its short kinetics most users split the daily intake.

Strategy Dose Frequency Length
Recomp 5 mg TID (15 mg) Every 6 h 4-6 wk
Bulk 7.5 mg BID (15 mg) Morning/Pre-WO 6-8 wk

Side-Effects

  • Suppression: Similar to RAD-140 when total daily dose >15 mg; full PCT needed.
  • Insomnia: CNS stimulation; avoid evening doses.
  • Appetite: Mild GI discomfort reported first week.

Bottom Line: LGD-3303 offers faster, drier gains than LGD-4033 at the cost of multiple daily dosing and comparable suppression.

Common mistakes

The trap is assuming that because it shares the LGD name, it shares the same practical profile. Another is letting novelty outrank risk management and post-cycle planning.

Comparison notes

Compared with LGD-4033, LGD-3303 is usually treated as more niche and less well characterized in the real world.

Safety & monitoring
Side effects

  • Natural suppression with reduced fertility and testicular output

  • Suppression, worsened lipids, and an evidence base that is much thinner than users assume

Monitoring

  • CBC / hematocrit

  • blood pressure

  • lipid panel

Avoid if

  • Uncontrolled hypertension or untreated cardiovascular disease

  • Pre-existing severe infertility concerns unless that risk is accepted and managed

Add to Cycle Builder ← Browse